Back to search results

Improving Diabetes Control with Smart Insulin Pens and Telemedicine

This study is looking at whether using a smart insulin pen called InPen, along with continuous glucose monitors (CGMs) and telemedicine, can help people with diabetes manage their blood sugar better than using traditional insulin pens. The study aims to see if this approach leads to improved blood sugar control and better health outcomes. You might be able to join if you are at least 18 years old and have been using multiple daily insulin injections (MDI) for at least three months. The main goal is to see how much hyperglycemia (high blood sugar) changes after three months. The current status of this study is unclear, and it plans to enroll 50 participants.

Study design
This interventional study plans to enroll 50 participants. It compares the InPen Smart insulin pen with traditional insulin pens.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for changes in hyperglycemia, measured at 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06918977

Improving Glycemic Control With Telemedicine and Smart Insulin Pens

Recruiting
NAAges 18+InterventionalPrevention
University of Maryland, Baltimore
~50 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:InPen Smart insulin pentraditional/standard insulin pen

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in hyperglycemia
Measured over 3 months

Conditions

Diabetes Mellitus

Explore related trials

Diabetes Mellitus

Where it's being run

2 sites across 1 states
Maryland2

Who to contact

William Scott, MS
[email protected]
4106057000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥18 years of age
MDI insulin treated (receiving MDI for at least 3 months prior to the study)

Exclusion

DM patients not treated with MDI for at least 3 months (i.e diet only, any combination of non-insulin antidiabetic drugs only, basal insulin only or bolus/short acting insulin only)
Patients with DM at the time of screening on insulin pumps
Pregnant patients
Patients with extensive skin disease or allergies that preclude wearing the CGM sensor
Patients who have end-stage renal disease requiring dialysis
Patients with significant psychiatric illness or any other condition rendering the subject incapable of understanding the objectives and potential consequences of the study
Patients who receive hydroxyurea or who are on long (chronic) treatment with acetaminophen
Patients who were started on non-insulin DM medications or had a dose change within 60 days or less prior to study participation
Patient does not have or not able to gain access to a smartphone which is compatible with the necessary applications for DAT

What this trial measures

  • Change in hyperglycemia3 months

    This will be evaluated by decrease HbA1c